AstraZeneca to pay $200M upfront for Sino Biopharmaceutical’s COPD drug license deal
Seeking Alpha ·
AstraZeneca ( AZN ) has secured global rights (excluding China) to an experimental chronic obstructive pulmonary disease (COPD) treatment, TQC3721, from a subsidiary of Hong Kong-listed Sino Biopharmaceutical ( SBMFF ) and will pay $200 million upfront , according to a report by Reuters .
DYAX Investor Sentiment
Bullish (Long) 28% · Bearish (Short) 72%
404 participants
Related News
- Concorde International Group receives Nasdaq minimum bid price notice
- Got $1,000? 2 Red-Hot Tech Stocks Setting the Market on Fire in 2026
- Apple reportedly testing DRAM chips from China’s CXMT
- Prediction markets see Nasdaq-100 rally cooling after AI surge
- IperionX prices $50M U.S. public offering at $21.98/ADS
- Kalshi bets shift to Quantum, semiconductor stakes over OpenAI government deal